Buprenorphine and Ziprasidone: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Ziprasidone
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Taking buprenorphine and ziprasidone together needs a close look from your care team. Both medicines can affect the heart's rhythm in a way that shows up on an EKG (called QT prolongation), and using them together can add up and raise the risk of a dangerous heartbeat.
On top of that, both can slow down your breathing and make you very sleepy, and together they can raise the chance of a rare but serious reaction called serotonin syndrome (things like agitation, sweating, shakiness, or a fast heartbeat). This combination is generally considered off-limits. Please don't stop either drug on your own. Talk with your doctor or pharmacist so they can pick the safest plan for you.
Contraindicated combination. Direction: additive toxicity, not a metabolic prodrug issue (neither requires the other for activation).
- QT prolongation: additive QTc effect from both agents raises risk of ventricular arrhythmia (including torsades).
- CNS/respiratory depression: additive effect increases sedation and hypoventilation risk.
- Serotonin syndrome: additive serotonergic effect.
Evidence: probable. Onset: unspecified. Management: avoid concurrent use where possible. Do not withhold MAT to manage opioid use disorder; discontinuation of the CNS depressant (ziprasidone) is generally preferred. If co-use is unavoidable, monitor ECG/QTc, sedation, and for serotonin syndrome (especially at initiation and dose changes); consider alternatives for anxiety/psychosis.
What happens
An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression
Interaction Deep Dive
The combined administration of ziprasidone and buprenorphine is contraindicated because it can heighten the likelihood of QT prolongation along with serious ventricular arrhythmias. In addition, taking buprenorphine together with ziprasidone can raise the potential for serotonin syndrome and may intensify CNS depression3. When such combined use cannot be avoided, watch for serotonin syndrome, especially at the start of treatment and whenever doses are changed. Should serotonin syndrome be suspected, stop buprenorphine 1. Patients on CNS depressant therapy, ziprasidone included, should not be denied access to medication-assisted treatment (MAT) agents such as buprenorphine. Even though concurrent use raises the risk of serious adverse effects, overdose, and death, withholding MAT can produce a greater risk of morbidity and mortality tied to opioid use disorder. In most situations, stopping the CNS depressant is the preferred approach. When concurrent use is required, exercise careful monitoring and management; consider reducing the CNS depressant to the lowest dose that remains effective or turning to alternative treatments for anxiety or insomnia 2.
Why it happens (mechanism)
Additive CNS depression; additive serotonergic effects; additive QT interval prolongation
How to manage this interaction
This pairing is flagged as one to avoid, but your care team can manage it safely. Keep taking both exactly as prescribed until you speak with your prescriber or pharmacist. Do not stop on your own, especially buprenorphine, which is important for treating opioid use disorder.
- Your team may check your heart rhythm (an EKG) and watch for QT changes.
- They will watch for excess sleepiness or slowed breathing.
- They will watch for serotonin syndrome, especially when starting or adjusting doses.
- Often the preferred step is to adjust or switch the other medicine (ziprasidone) rather than remove buprenorphine.
Report agitation, sweating, tremor, fast heartbeat, confusion, or feeling very drowsy right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) A Swedish epidemiological study found that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also took benzodiazepines or other CNS depressants (for instance, medications used for insomnia) have a heightened risk of death. From July 1, 2005 through December 31, 2012, investigators evaluated the risk of fatal overdose, non-overdose related death, and all-cause death by comparing intervals when CNS depressants were prescribed with intervals lacking CNS depressant therapy in MAT patients (aged 18 to 50). The findings showed an increased risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01) with MAT combined with benzodiazepine treatment; however, these data were not deemed statistically significant. Although the results indicated a raised risk of fatal overdose, non-overdose mortality, and all-cause mortality during periods when MAT and non-benzodiazepines were given together, only the figures for fatal overdose and all-cause mortality reached statistical significance; HR 2.34 (95% CI, 1.37 to 3.99) and HR 1.33 (95% CI, 1.12 to 2.45), respectively. When the benzodiazepine cohort and the non-benzodiazepine cohort data are compared, the non-benzodiazepine cohort data also becomes statistically insignificant 2.
b) A study of pooled nationwide death certificate data from 2010 to 2014 identified 3495 drug overdose deaths reported in 2014. Methadone and other CNS depressants were commonly implicated in those deaths. Simultaneous ALPRAZolam use was noted in 18.1% of cases, followed by oxyCODONE (10.1%), cocaine (9.6%), heroin (9%), and diazePAM (6.6%). The FDA documented 322 drug overdose deaths in 2014 that involved buprenorphine. Among these 322 deaths, 32.9% involved ALPRAZolam, 17.4% involved clonazePAM, 11.2% involved diazePAM, 11.2% involved heroin, and 9.9% involved fentaNYL. The absolute count of methadone-involved deaths was 10 times that of buprenorphine-involved deaths, though confounding factors and differences in drug utilization were not taken into account. Whether the risk of overdose death with concomitant CNS depressant drugs differed between buprenorphine and methadone remains unknown 2.
Common questions
Can I take Buprenorphine and Ziprasidone together?
Buprenorphine and ziprasidone together can add up to cause dangerous heart rhythm changes, heavy sedation, and serotonin syndrome, so this combination is generally avoided. Do not stop either drug yourself; contact your prescriber or pharmacist to arrange a safer plan. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Ziprasidone interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Ziprasidone interaction managed?
This pairing is flagged as one to avoid, but your care team can manage it safely. Keep taking both exactly as prescribed until you speak with your prescriber or pharmacist. Do not stop on your own, especially buprenorphine, which is important for treating opioid use disorder. Your team may check your heart rhythm (an EKG) and watch for QT changes. They will watch for excess sleepiness or slowed br… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Ziprasidone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
- Product Information: GEODON(R) oral capsules, ziprasidone oral capsules. Viatris Specialty LLC(per FDA), Morgantown, WV, 2025. DailyMed
Keep reading about Buprenorphine
Keep reading about Ziprasidone
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist